It's time to compare anemia management strategies in hemodialysis

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 4, 2010, Pages 740-742

  Coyne, Daniel W ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; IRON DEXTRAN;

ANEMIA; CARDIOVASCULAR DISEASE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; MORTALITY; OXIDATIVE STRESS; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANEMIA; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ERYTHROPOIESIS; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMOGLOBINS; HUMANS; IRON COMPOUNDS; KIDNEY DISEASES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77950932923     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02490409     Document Type: Review

References (34)

1. Spiegel DM, Chertow GM: Lost without directions: Lessons from the anemia debate and the Drive study. Clin J Am Soc Nephrol 4: 1009-1010, 2009
2. Coyne DW: A comprehensive vision for intravenous iron therapy. Am J Kidney Dis 52[Suppl 1]:S14-S20, 2008
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. [see comment]. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
4. Epogen Package Insert Revised April 2009, http://www. epogen.com/pdf/epogen-pi.pdf
5. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
6. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924, 2008 (Pubitemid 351397066)
7. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975-984, 2007 (Pubitemid 46434515)
8. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
9. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
10. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44: 866-876, 2004 (Pubitemid 39445919)
11. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAl-lister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
12. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372-379, 2008 (Pubitemid 351240658)
13. Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR, Agarwal R, Eschbach JW, Fadem SZ, Trout JR, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61: 1830-1839, 2002 (Pubitemid 34437938)
14. Coyne DW, Adkinson NF, Nissenson AR, Fishbane S, Agarwal R, Eschbach JW, Michael B, Folkert V, Batlle D, Trout JR, Dahl N, Myirski P, Strobos J, Warnock DG: Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextrantolerant patients. Kidney Int 63: 217-224, 2003 (Pubitemid 35463924)
15. Folkert VW, Michael B, Agarwal R, Coyne DW, Dahl N, Myirski P, Warnock DG: Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (> or =250 mg) administration. Am J Kidney Dis 41: 651-657, 2003 (Pubitemid 36278383)
16. Michael B, Coyne DW, Folkert VW, Dahl NV, Warnock DG: Sodium ferric gluconate complex in haemodialysis patients: A prospective evaluation of long-term safety. Nephrol Dial Transplant 19: 1576-1580, 2004 (Pubitemid 38786753)
17. Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS: Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clinical Practice 96: c63-c66, 2004 (Pubitemid 38456612)
18. Fishbane S: Safety in iron management. [see comment]. Am J Kidney Dis 41: 18-26, 2003
19. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 37: 300-307, 2001 (Pubitemid 32116021)
20. Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36: 88-97, 2000 (Pubitemid 30432569)
21. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner, L: Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 52: 907-915, 2008
22. Michael B, Fishbane S, Coyne DW, Agarwal R, Warnock DG: Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex. Nat Clin Pract Nephrol 2: 92-100, 2006 (Pubitemid 43355217)
23. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21: 378-382, 2006 (Pubitemid 43159991)
24. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13: 734-744, 2002 (Pubitemid 34183940)
25. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15: 1623-1632, 2004 (Pubitemid 38679688)
26. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis 52: 897-906, 2008
27. Brewster UC: Intravenous iron therapy in end-stage renal disease. Semin Dial 19: 285-290, 2006 (Pubitemid 44091702)
28. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279-2289, 2004 (Pubitemid 38670014)
29. Lim CS, Vaziri ND: The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 65: 1802-1809, 2004 (Pubitemid 38591029)
30. Leehey DJ, Palubiak DJ, Chebrolu S, Agarwal R: Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: A pilot study. Nephrol Dial Transplant 20: 135-140, 2005 (Pubitemid 40207618)
31. Besarab A, Goodkin DA, Nissenson AR: The normal hematocrit study-follow-up. N Engl J Med 358: 433-434, 2008
32. Food and Drug Administration: FDA Advisory Committee Briefing Document; Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee; and errata, http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf and http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4315b1-02-FDA-Errata%20.pdf, September 2007
33. Coyne DW: From anemia trials to clinical practice: Understanding the risks and benefits when setting goals for therapy. Semin Dial 21: 212-216, 2008
34. Ibrahim HN, Foley RN, Zhang R, Gilbertson DT, Collins AJ: Parenteral iron use: Possible contribution to exceeding target hemoglobin in hemodialysis patients. Clin J Am Soc Nephrol 4: 623-629, 2009